| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 91 | 2021 | 1866 | 5.120 |
Why?
|
| Carcinoma, Medullary | 41 | 2017 | 248 | 4.230 |
Why?
|
| Proto-Oncogene Proteins c-ret | 41 | 2021 | 370 | 4.130 |
Why?
|
| Calcitonin | 56 | 2019 | 186 | 3.260 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 30 | 2017 | 115 | 3.170 |
Why?
|
| Carcinoma, Neuroendocrine | 15 | 2021 | 716 | 2.440 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 23 | 2010 | 661 | 2.010 |
Why?
|
| Multiple Endocrine Neoplasia | 17 | 2020 | 57 | 1.800 |
Why?
|
| Activating Transcription Factor 4 | 3 | 2018 | 73 | 1.740 |
Why?
|
| Calcitonin Gene-Related Peptide | 23 | 2017 | 163 | 1.670 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2021 | 4757 | 1.340 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2015 | 2488 | 1.280 |
Why?
|
| Thyroid Gland | 14 | 2017 | 355 | 1.230 |
Why?
|
| Drosophila Proteins | 16 | 2001 | 858 | 1.190 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 10 | 2015 | 53 | 1.090 |
Why?
|
| Pheochromocytoma | 21 | 2018 | 281 | 1.060 |
Why?
|
| Thyroidectomy | 15 | 2020 | 486 | 1.000 |
Why?
|
| Acromegaly | 5 | 2010 | 27 | 0.960 |
Why?
|
| Adrenal Gland Neoplasms | 18 | 2018 | 489 | 0.930 |
Why?
|
| Osteoporosis | 6 | 2019 | 241 | 0.900 |
Why?
|
| Endocrine Gland Neoplasms | 4 | 2010 | 42 | 0.820 |
Why?
|
| Human Growth Hormone | 4 | 2010 | 82 | 0.770 |
Why?
|
| Apoptosis | 5 | 2021 | 7591 | 0.760 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2021 | 89 | 0.760 |
Why?
|
| Bone Density | 8 | 2013 | 476 | 0.750 |
Why?
|
| Pyridines | 5 | 2021 | 1244 | 0.730 |
Why?
|
| Antineoplastic Agents | 15 | 2021 | 14289 | 0.720 |
Why?
|
| Germ-Line Mutation | 14 | 2017 | 1046 | 0.700 |
Why?
|
| Point Mutation | 15 | 2004 | 769 | 0.700 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 272 | 0.700 |
Why?
|
| Bone Resorption | 7 | 2019 | 138 | 0.700 |
Why?
|
| Genetic Testing | 13 | 2018 | 1589 | 0.690 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2019 | 20 | 0.690 |
Why?
|
| Hypophosphatemia | 1 | 2019 | 26 | 0.680 |
Why?
|
| Mandibular Osteotomy | 1 | 2019 | 33 | 0.680 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2018 | 35 | 0.670 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 76 | 0.650 |
Why?
|
| Bone Density Conservation Agents | 6 | 2019 | 198 | 0.640 |
Why?
|
| Alternative Splicing | 8 | 2004 | 584 | 0.610 |
Why?
|
| Quinazolines | 3 | 2019 | 923 | 0.610 |
Why?
|
| Osteonecrosis | 4 | 2010 | 53 | 0.600 |
Why?
|
| Carcinoma | 27 | 2012 | 2578 | 0.590 |
Why?
|
| Piperidines | 3 | 2019 | 1035 | 0.590 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2018 | 270 | 0.580 |
Why?
|
| RNA Precursors | 6 | 2002 | 137 | 0.580 |
Why?
|
| Diphosphonates | 6 | 2010 | 262 | 0.570 |
Why?
|
| Proto-Oncogenes | 8 | 2001 | 202 | 0.570 |
Why?
|
| Imidazoles | 2 | 2021 | 999 | 0.560 |
Why?
|
| Humans | 196 | 2022 | 261506 | 0.540 |
Why?
|
| Jaw Diseases | 3 | 2010 | 21 | 0.540 |
Why?
|
| Pituitary Neoplasms | 7 | 2009 | 203 | 0.510 |
Why?
|
| Exons | 13 | 2013 | 1328 | 0.490 |
Why?
|
| Calcitriol | 6 | 1994 | 127 | 0.490 |
Why?
|
| Osteomalacia | 4 | 2019 | 36 | 0.470 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 9 | 2006 | 141 | 0.470 |
Why?
|
| Bone Diseases, Metabolic | 3 | 2010 | 84 | 0.440 |
Why?
|
| RNA Processing, Post-Transcriptional | 6 | 1998 | 154 | 0.430 |
Why?
|
| Calcium | 16 | 2013 | 1537 | 0.430 |
Why?
|
| Trans-Splicing | 2 | 2002 | 6 | 0.430 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1129 | 0.420 |
Why?
|
| Pituitary Gland | 3 | 2008 | 150 | 0.410 |
Why?
|
| Osteolysis | 3 | 2022 | 80 | 0.410 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2012 | 1756 | 0.400 |
Why?
|
| Receptors, Somatotropin | 1 | 2010 | 17 | 0.390 |
Why?
|
| Teriparatide | 3 | 2011 | 11 | 0.390 |
Why?
|
| Bone and Bones | 6 | 2013 | 619 | 0.380 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 135 | 0.370 |
Why?
|
| Enhancer Elements, Genetic | 6 | 1999 | 467 | 0.360 |
Why?
|
| Male | 88 | 2021 | 123000 | 0.360 |
Why?
|
| Amyloidosis | 4 | 2002 | 176 | 0.360 |
Why?
|
| Hypercalcemia | 8 | 2009 | 137 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 10 | 9 | 2003 | 135 | 0.360 |
Why?
|
| Endocrine System | 2 | 2001 | 36 | 0.360 |
Why?
|
| Pedigree | 18 | 2017 | 1890 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2019 | 2359 | 0.350 |
Why?
|
| Bone Neoplasms | 7 | 2019 | 2576 | 0.350 |
Why?
|
| Base Sequence | 24 | 2004 | 4917 | 0.350 |
Why?
|
| Introns | 5 | 1999 | 432 | 0.340 |
Why?
|
| Adult | 67 | 2020 | 77950 | 0.340 |
Why?
|
| Female | 95 | 2020 | 141928 | 0.340 |
Why?
|
| Endocrine System Diseases | 2 | 2020 | 83 | 0.330 |
Why?
|
| Down-Regulation | 4 | 2019 | 2074 | 0.330 |
Why?
|
| Endocrinology | 3 | 2016 | 139 | 0.330 |
Why?
|
| Adenoma | 6 | 2008 | 716 | 0.320 |
Why?
|
| Molecular Sequence Data | 22 | 2008 | 6089 | 0.320 |
Why?
|
| Pyrimidines | 1 | 2021 | 3518 | 0.320 |
Why?
|
| Mutation | 25 | 2017 | 15179 | 0.320 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 488 | 0.320 |
Why?
|
| Mass Screening | 4 | 2015 | 1509 | 0.320 |
Why?
|
| RNA, Messenger | 17 | 2013 | 6150 | 0.320 |
Why?
|
| Octreotide | 4 | 2008 | 118 | 0.310 |
Why?
|
| DNA, Neoplasm | 6 | 2008 | 1910 | 0.300 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 295 | 0.300 |
Why?
|
| Calcium, Dietary | 2 | 1998 | 56 | 0.290 |
Why?
|
| Adolescent | 39 | 2020 | 31252 | 0.290 |
Why?
|
| Somatostatin | 4 | 1989 | 114 | 0.290 |
Why?
|
| Paraganglioma | 4 | 2018 | 170 | 0.290 |
Why?
|
| Multiple Myeloma | 5 | 2022 | 2138 | 0.290 |
Why?
|
| Neuropeptides | 4 | 1987 | 154 | 0.280 |
Why?
|
| Animals | 45 | 2021 | 59536 | 0.280 |
Why?
|
| Gene Expression Regulation | 6 | 2015 | 4053 | 0.280 |
Why?
|
| RNA Splicing | 5 | 1999 | 370 | 0.280 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2008 | 691 | 0.270 |
Why?
|
| DNA Mutational Analysis | 10 | 2017 | 2283 | 0.270 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 1990 | 220 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 14 | 2013 | 5395 | 0.260 |
Why?
|
| Middle Aged | 62 | 2019 | 86204 | 0.260 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 5159 | 0.250 |
Why?
|
| Neoplasm Proteins | 6 | 2011 | 3230 | 0.250 |
Why?
|
| Mice | 26 | 2021 | 34495 | 0.240 |
Why?
|
| Osteoclasts | 4 | 2022 | 165 | 0.240 |
Why?
|
| Transcription, Genetic | 6 | 2015 | 3154 | 0.240 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2005 | 135 | 0.230 |
Why?
|
| Hyperparathyroidism | 5 | 2005 | 93 | 0.230 |
Why?
|
| Osteogenesis | 4 | 2019 | 271 | 0.220 |
Why?
|
| Neoplasms | 11 | 2019 | 15193 | 0.220 |
Why?
|
| Osteoblasts | 5 | 2022 | 370 | 0.220 |
Why?
|
| Osteosarcoma | 2 | 2011 | 929 | 0.220 |
Why?
|
| Aged | 46 | 2019 | 70117 | 0.220 |
Why?
|
| Bone Remodeling | 2 | 2005 | 104 | 0.210 |
Why?
|
| Cyclic AMP | 5 | 1995 | 358 | 0.210 |
Why?
|
| Anilides | 2 | 2017 | 268 | 0.210 |
Why?
|
| Parathyroid Hormone | 9 | 2006 | 194 | 0.210 |
Why?
|
| Lichen Planus | 1 | 2002 | 22 | 0.210 |
Why?
|
| Adenoviruses, Human | 1 | 2002 | 181 | 0.210 |
Why?
|
| Pentagastrin | 6 | 1997 | 10 | 0.210 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 3 | 1996 | 42 | 0.200 |
Why?
|
| Chromosome Aberrations | 2 | 2008 | 1960 | 0.200 |
Why?
|
| Young Adult | 11 | 2020 | 21445 | 0.200 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 1217 | 0.200 |
Why?
|
| DNA Primers | 3 | 1999 | 1399 | 0.200 |
Why?
|
| Hyperinsulinism | 3 | 1996 | 85 | 0.200 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1999 | 239 | 0.200 |
Why?
|
| Prolactinoma | 1 | 2000 | 11 | 0.200 |
Why?
|
| Periodicals as Topic | 2 | 2016 | 338 | 0.200 |
Why?
|
| Spliceosomes | 1 | 2001 | 75 | 0.190 |
Why?
|
| Aminoquinolines | 1 | 2000 | 46 | 0.190 |
Why?
|
| Risk Factors | 13 | 2019 | 17523 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2010 | 630 | 0.190 |
Why?
|
| Phenotype | 14 | 2017 | 6295 | 0.190 |
Why?
|
| Mice, Knockout | 10 | 2017 | 5710 | 0.190 |
Why?
|
| 3T3 Cells | 4 | 2002 | 355 | 0.190 |
Why?
|
| Patient Selection | 3 | 2020 | 2055 | 0.190 |
Why?
|
| Dopamine Agonists | 1 | 2000 | 85 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2021 | 7226 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 9 | 2008 | 3203 | 0.180 |
Why?
|
| Mesenchymoma | 1 | 2000 | 14 | 0.180 |
Why?
|
| Heterozygote | 4 | 2017 | 1020 | 0.180 |
Why?
|
| Hypoglycemia | 3 | 1996 | 213 | 0.180 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 1996 | 299 | 0.180 |
Why?
|
| Luteinizing Hormone | 1 | 2000 | 165 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2013 | 2947 | 0.180 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 644 | 0.180 |
Why?
|
| RNA, Catalytic | 1 | 1999 | 37 | 0.180 |
Why?
|
| Blotting, Western | 3 | 2017 | 3536 | 0.180 |
Why?
|
| Carcinoma, Islet Cell | 3 | 2010 | 35 | 0.180 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2000 | 241 | 0.180 |
Why?
|
| RNA, Viral | 1 | 2002 | 671 | 0.180 |
Why?
|
| Phosphates | 2 | 2000 | 187 | 0.170 |
Why?
|
| Gigantism | 1 | 1999 | 15 | 0.170 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 37 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 44 | 0.170 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2006 | 221 | 0.170 |
Why?
|
| Adrenalectomy | 5 | 2004 | 188 | 0.170 |
Why?
|
| Child | 26 | 2020 | 29154 | 0.170 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1999 | 68 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2019 | 4938 | 0.170 |
Why?
|
| Skin Diseases | 3 | 1996 | 349 | 0.170 |
Why?
|
| HeLa Cells | 10 | 2008 | 1643 | 0.160 |
Why?
|
| Lactation | 2 | 2013 | 210 | 0.160 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10331 | 0.160 |
Why?
|
| Diseases in Twins | 1 | 1999 | 99 | 0.160 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2019 | 82 | 0.160 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.160 |
Why?
|
| Receptors, Cell Surface | 2 | 1999 | 862 | 0.160 |
Why?
|
| Threonine | 2 | 2015 | 161 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.160 |
Why?
|
| Dioxygenases | 1 | 2019 | 159 | 0.160 |
Why?
|
| Bone Diseases | 1 | 2019 | 143 | 0.160 |
Why?
|
| Time Factors | 10 | 2020 | 12926 | 0.160 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14551 | 0.160 |
Why?
|
| Technetium Tc 99m Sestamibi | 3 | 2003 | 121 | 0.160 |
Why?
|
| Benzenesulfonates | 2 | 2009 | 195 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 227 | 0.160 |
Why?
|
| Quinolones | 2 | 2009 | 160 | 0.160 |
Why?
|
| Peptides | 5 | 2017 | 1479 | 0.160 |
Why?
|
| Aged, 80 and over | 16 | 2018 | 29902 | 0.160 |
Why?
|
| Protein Precursors | 2 | 2013 | 240 | 0.160 |
Why?
|
| Fibula | 1 | 2019 | 146 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 1998 | 109 | 0.150 |
Why?
|
| Histone Demethylases | 1 | 2019 | 144 | 0.150 |
Why?
|
| Phosphorylation | 4 | 2015 | 4804 | 0.150 |
Why?
|
| Gene Expression | 6 | 2003 | 3570 | 0.150 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 1998 | 81 | 0.150 |
Why?
|
| Transfection | 5 | 2001 | 2944 | 0.150 |
Why?
|
| Parathyroid Glands | 6 | 2003 | 127 | 0.150 |
Why?
|
| Goiter | 1 | 1997 | 17 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 305 | 0.150 |
Why?
|
| von Hippel-Lindau Disease | 4 | 2004 | 115 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 189 | 0.150 |
Why?
|
| RNA-Binding Proteins | 4 | 1999 | 984 | 0.150 |
Why?
|
| Spinal Neoplasms | 2 | 2000 | 631 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2016 | 5539 | 0.150 |
Why?
|
| Thymidine Phosphorylase | 1 | 2016 | 23 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 2508 | 0.140 |
Why?
|
| Codon | 4 | 2004 | 241 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2017 | 291 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 115 | 0.140 |
Why?
|
| Gene Deletion | 5 | 2013 | 1442 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2013 | 5270 | 0.140 |
Why?
|
| Double-Blind Method | 4 | 2019 | 2588 | 0.140 |
Why?
|
| HEK293 Cells | 2 | 2019 | 1489 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 275 | 0.140 |
Why?
|
| Vitamin D | 3 | 2013 | 261 | 0.140 |
Why?
|
| Femoral Fractures | 1 | 2016 | 50 | 0.140 |
Why?
|
| Neural Crest | 1 | 1996 | 85 | 0.130 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 241 | 0.130 |
Why?
|
| Physician's Role | 1 | 2018 | 238 | 0.130 |
Why?
|
| Spinal Fractures | 1 | 2016 | 132 | 0.130 |
Why?
|
| Spinal Cord Compression | 1 | 2016 | 151 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2019 | 11965 | 0.130 |
Why?
|
| Prostatic Neoplasms | 3 | 2009 | 5767 | 0.130 |
Why?
|
| Genotype | 10 | 2017 | 4109 | 0.130 |
Why?
|
| DNA-Binding Proteins | 4 | 2002 | 4821 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Tongue Neoplasms | 1 | 1996 | 246 | 0.120 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2014 | 10 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2017 | 575 | 0.120 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 372 | 0.120 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 502 | 0.120 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 425 | 0.120 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 323 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2019 | 3101 | 0.120 |
Why?
|
| Biopsy, Needle | 2 | 1997 | 1363 | 0.120 |
Why?
|
| Retrospective Studies | 22 | 2021 | 37905 | 0.120 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2013 | 42 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2013 | 840 | 0.120 |
Why?
|
| Gene Ontology | 1 | 2013 | 80 | 0.120 |
Why?
|
| DNA | 8 | 1999 | 2693 | 0.120 |
Why?
|
| Bone Marrow | 2 | 2019 | 2358 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 3639 | 0.110 |
Why?
|
| Calcification, Physiologic | 1 | 2013 | 56 | 0.110 |
Why?
|
| Dexamethasone | 3 | 1987 | 1450 | 0.110 |
Why?
|
| Oncogene Proteins | 3 | 2004 | 354 | 0.110 |
Why?
|
| Plasmids | 4 | 2001 | 837 | 0.110 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.110 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 159 | 0.110 |
Why?
|
| Publishing | 1 | 2015 | 220 | 0.110 |
Why?
|
| Societies, Medical | 5 | 2015 | 1335 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 1064 | 0.110 |
Why?
|
| Pyrroles | 1 | 2017 | 576 | 0.110 |
Why?
|
| Growth Hormone | 3 | 2003 | 226 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2019 | 650 | 0.110 |
Why?
|
| Treatment Outcome | 14 | 2019 | 32848 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2004 | 10035 | 0.100 |
Why?
|
| Radiography | 5 | 2002 | 1904 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 1165 | 0.100 |
Why?
|
| Farnesyltranstransferase | 2 | 2009 | 122 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 621 | 0.100 |
Why?
|
| Liraglutide | 1 | 2011 | 16 | 0.100 |
Why?
|
| Receptors, Drug | 3 | 1996 | 48 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Receptors, Glucagon | 1 | 2011 | 36 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 7 | 2010 | 5061 | 0.100 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2011 | 60 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 1037 | 0.100 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2011 | 67 | 0.100 |
Why?
|
| Radioimmunoassay | 6 | 2004 | 191 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 2315 | 0.100 |
Why?
|
| Breast Neoplasms | 6 | 2010 | 15694 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 876 | 0.100 |
Why?
|
| Indoles | 1 | 2017 | 1009 | 0.100 |
Why?
|
| Age Factors | 6 | 2017 | 5377 | 0.100 |
Why?
|
| Skin Neoplasms | 3 | 2008 | 4654 | 0.100 |
Why?
|
| Proteins | 3 | 1998 | 1963 | 0.100 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 586 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1008 | 0.100 |
Why?
|
| Parathyroid Neoplasms | 2 | 2004 | 185 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Genetic Counseling | 3 | 2018 | 380 | 0.090 |
Why?
|
| Potassium Channels | 3 | 1996 | 162 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1994 | 1039 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 7548 | 0.090 |
Why?
|
| Drug Approval | 1 | 2011 | 178 | 0.090 |
Why?
|
| Cell Survival | 1 | 2017 | 3045 | 0.090 |
Why?
|
| Cell Line | 12 | 1995 | 5114 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 1491 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 332 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 430 | 0.090 |
Why?
|
| Amino Acid Sequence | 7 | 2008 | 4233 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Minerals | 2 | 2007 | 71 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 5 | 1989 | 542 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2015 | 1620 | 0.090 |
Why?
|
| Carcinoid Tumor | 2 | 2010 | 280 | 0.090 |
Why?
|
| Diabetes Insipidus | 1 | 2009 | 26 | 0.090 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2009 | 96 | 0.080 |
Why?
|
| Hypopituitarism | 1 | 2009 | 33 | 0.080 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Viral Proteins | 2 | 2002 | 435 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6207 | 0.080 |
Why?
|
| RANK Ligand | 2 | 2022 | 119 | 0.080 |
Why?
|
| Syndrome | 4 | 2008 | 1351 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 1450 | 0.080 |
Why?
|
| Osteitis Deformans | 1 | 1988 | 34 | 0.080 |
Why?
|
| Genes, Suppressor | 1 | 2008 | 25 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.080 |
Why?
|
| Hemangiopericytoma | 1 | 2008 | 56 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1493 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 3719 | 0.080 |
Why?
|
| Jaw Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
| Neoplasm Metastasis | 10 | 2017 | 5112 | 0.080 |
Why?
|
| Palliative Care | 1 | 2000 | 2037 | 0.080 |
Why?
|
| Rats | 12 | 1998 | 6086 | 0.080 |
Why?
|
| Sulfonylurea Compounds | 3 | 1996 | 32 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 1143 | 0.080 |
Why?
|
| Phorbol Esters | 1 | 1987 | 39 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1130 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1824 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2006 | 1423 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 14889 | 0.080 |
Why?
|
| Hirschsprung Disease | 3 | 1996 | 46 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 2432 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2003 | 1301 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.080 |
Why?
|
| Prevalence | 3 | 2014 | 3260 | 0.080 |
Why?
|
| Parathyroid Hormone-Related Protein | 4 | 2006 | 24 | 0.070 |
Why?
|
| Age of Onset | 2 | 2013 | 827 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 257 | 0.070 |
Why?
|
| Obesity | 2 | 2017 | 2884 | 0.070 |
Why?
|
| Reoperation | 5 | 2004 | 1382 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2008 | 315 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 5 | 2017 | 6942 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 649 | 0.070 |
Why?
|
| Thyrotoxicosis | 1 | 2006 | 22 | 0.070 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2001 | 223 | 0.070 |
Why?
|
| Restriction Mapping | 3 | 1999 | 264 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2006 | 81 | 0.070 |
Why?
|
| Prospective Studies | 7 | 2017 | 12873 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1085 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2019 | 2450 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2195 | 0.070 |
Why?
|
| Lymphatic Metastasis | 3 | 2013 | 4844 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 1664 | 0.070 |
Why?
|
| Norway | 1 | 2005 | 30 | 0.070 |
Why?
|
| Osteitis | 1 | 2005 | 17 | 0.070 |
Why?
|
| Cells, Cultured | 6 | 2008 | 5637 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2008 | 2086 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 1996 | 4078 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2005 | 87 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2008 | 747 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2017 | 9244 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2004 | 27 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 1993 | 1429 | 0.060 |
Why?
|
| Nuclear Proteins | 5 | 2022 | 3343 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1054 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 108 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2013 | 1152 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2330 | 0.060 |
Why?
|
| United States | 6 | 2013 | 15433 | 0.060 |
Why?
|
| Risk | 5 | 2014 | 1972 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8865 | 0.060 |
Why?
|
| Comorbidity | 1 | 2010 | 2352 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2005 | 170 | 0.060 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 1983 | 4 | 0.060 |
Why?
|
| Gliosarcoma | 1 | 2003 | 29 | 0.060 |
Why?
|
| Child, Preschool | 8 | 2014 | 16273 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2004 | 331 | 0.060 |
Why?
|
| Magnesium | 1 | 2004 | 160 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2015 | 15862 | 0.060 |
Why?
|
| Hypocalcemia | 2 | 2003 | 59 | 0.060 |
Why?
|
| Preimplantation Diagnosis | 1 | 2003 | 47 | 0.060 |
Why?
|
| Homeostasis | 2 | 2005 | 950 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2008 | 1152 | 0.060 |
Why?
|
| Estrogens | 2 | 2007 | 751 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 1987 | 629 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2403 | 0.060 |
Why?
|
| Mycosis Fungoides | 1 | 2006 | 320 | 0.050 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2002 | 41 | 0.050 |
Why?
|
| Adrenal Gland Diseases | 2 | 1997 | 72 | 0.050 |
Why?
|
| Osteocytes | 1 | 2022 | 27 | 0.050 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 1999 | 14 | 0.050 |
Why?
|
| Chromosome Mapping | 3 | 1997 | 1471 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 2 | 2003 | 264 | 0.050 |
Why?
|
| Intestinal Absorption | 2 | 2006 | 211 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2006 | 842 | 0.050 |
Why?
|
| Hyperplasia | 6 | 2003 | 557 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2004 | 180 | 0.050 |
Why?
|
| Risk Assessment | 5 | 2019 | 6869 | 0.050 |
Why?
|
| Insulinoma | 1 | 2002 | 55 | 0.050 |
Why?
|
| Sulfonylurea Receptors | 3 | 1996 | 22 | 0.050 |
Why?
|
| Genetic Linkage | 2 | 1996 | 512 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 1084 | 0.050 |
Why?
|
| Sequence Tagged Sites | 1 | 2001 | 33 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2001 | 41 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2008 | 204 | 0.050 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 2 | 1998 | 9 | 0.050 |
Why?
|
| Histones | 2 | 2019 | 1466 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2011 | 1544 | 0.050 |
Why?
|
| Texas | 3 | 2017 | 6311 | 0.050 |
Why?
|
| Pruritus | 1 | 2002 | 87 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2002 | 330 | 0.050 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 2 | 1993 | 5 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 2390 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 573 | 0.050 |
Why?
|
| RNA Splice Sites | 1 | 2001 | 111 | 0.050 |
Why?
|
| Neck | 1 | 2003 | 383 | 0.050 |
Why?
|
| Adrenal Medulla | 3 | 1988 | 17 | 0.050 |
Why?
|
| Nociceptors | 1 | 2001 | 86 | 0.050 |
Why?
|
| Infant | 5 | 2014 | 13310 | 0.050 |
Why?
|
| Melanoma | 1 | 1998 | 5317 | 0.050 |
Why?
|
| Prolactin | 1 | 2000 | 155 | 0.050 |
Why?
|
| Family Health | 2 | 1999 | 325 | 0.050 |
Why?
|
| Gene Transfer Techniques | 2 | 2001 | 716 | 0.050 |
Why?
|
| Fetus | 1 | 2004 | 601 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 2 | 1976 | 27 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 4975 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2000 | 61 | 0.050 |
Why?
|
| Arthritis | 1 | 2001 | 139 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2003 | 731 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 4971 | 0.040 |
Why?
|
| Poly A | 2 | 1998 | 87 | 0.040 |
Why?
|
| Trisomy | 1 | 2000 | 231 | 0.040 |
Why?
|
| Actins | 1 | 2002 | 608 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1998 | 354 | 0.040 |
Why?
|
| Kinetics | 5 | 1998 | 2049 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 130 | 0.040 |
Why?
|
| Glucose | 1 | 2005 | 1248 | 0.040 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2001 | 172 | 0.040 |
Why?
|
| Adipokines | 1 | 2019 | 96 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2000 | 602 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2019 | 260 | 0.040 |
Why?
|
| Neurotensin | 3 | 1983 | 8 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2019 | 111 | 0.040 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 1995 | 48 | 0.040 |
Why?
|
| Calcium Radioisotopes | 1 | 1998 | 6 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 1999 | 129 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 1999 | 123 | 0.040 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 1998 | 26 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 1 | 2019 | 188 | 0.040 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2019 | 160 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 334 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 792 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 229 | 0.040 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 1998 | 47 | 0.040 |
Why?
|
| Craniotomy | 1 | 2000 | 304 | 0.040 |
Why?
|
| Cysteine | 2 | 1996 | 214 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2004 | 2231 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 8873 | 0.040 |
Why?
|
| Chromatography, Gel | 3 | 1986 | 157 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 245 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 1555 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 173 | 0.040 |
Why?
|
| Methylation | 1 | 2019 | 597 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2002 | 810 | 0.040 |
Why?
|
| Insulin | 3 | 2005 | 1454 | 0.040 |
Why?
|
| Neck Dissection | 1 | 1999 | 290 | 0.040 |
Why?
|
| Mutagenesis | 2 | 2000 | 483 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 5673 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 1998 | 239 | 0.040 |
Why?
|
| Thyroiditis | 1 | 1997 | 18 | 0.040 |
Why?
|
| Niacinamide | 2 | 2009 | 421 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2011 | 1290 | 0.040 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 1997 | 28 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1999 | 639 | 0.040 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2016 | 30 | 0.040 |
Why?
|
| Sp7 Transcription Factor | 1 | 2016 | 27 | 0.040 |
Why?
|
| Neurofibroma | 1 | 1996 | 31 | 0.040 |
Why?
|
| Streptozocin | 1 | 1976 | 75 | 0.040 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1998 | 192 | 0.040 |
Why?
|
| Hypokalemia | 1 | 1976 | 55 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2005 | 1244 | 0.040 |
Why?
|
| Calcium Isotopes | 1 | 1996 | 8 | 0.040 |
Why?
|
| Erythema Multiforme | 1 | 1996 | 14 | 0.040 |
Why?
|
| Absorption | 1 | 1996 | 81 | 0.040 |
Why?
|
| Stomach Diseases | 1 | 1976 | 62 | 0.040 |
Why?
|
| Centromere | 1 | 1996 | 97 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 76 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 1996 | 46 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 1997 | 92 | 0.030 |
Why?
|
| Osteocalcin | 1 | 1996 | 87 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 1996 | 78 | 0.030 |
Why?
|
| Methionine | 1 | 1996 | 159 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 1990 | 1005 | 0.030 |
Why?
|
| Lymph Node Excision | 2 | 2003 | 1959 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2022 | 1555 | 0.030 |
Why?
|
| Prognosis | 5 | 2017 | 21713 | 0.030 |
Why?
|
| Survival Analysis | 4 | 2016 | 9180 | 0.030 |
Why?
|
| Gallbladder | 1 | 1995 | 69 | 0.030 |
Why?
|
| Genetic Markers | 3 | 1993 | 974 | 0.030 |
Why?
|
| Biliary Tract | 1 | 1995 | 37 | 0.030 |
Why?
|
| Placebos | 2 | 2011 | 437 | 0.030 |
Why?
|
| Models, Genetic | 2 | 1998 | 1113 | 0.030 |
Why?
|
| Phenylurea Compounds | 2 | 2009 | 580 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 978 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 355 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 4744 | 0.030 |
Why?
|
| Cricetinae | 2 | 1999 | 706 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 1995 | 218 | 0.030 |
Why?
|
| Sepharose | 1 | 1994 | 32 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 499 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 1995 | 194 | 0.030 |
Why?
|
| Pancreatic Diseases | 1 | 1995 | 108 | 0.030 |
Why?
|
| Algorithms | 2 | 2020 | 3890 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 1995 | 205 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 381 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 633 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 290 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 310 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 1996 | 256 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 1993 | 52 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 7702 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2008 | 1382 | 0.030 |
Why?
|
| Norepinephrine | 3 | 1988 | 272 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2000 | 1467 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2005 | 700 | 0.030 |
Why?
|
| Biopsy | 2 | 2014 | 3443 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1989 | 1618 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 46 | 0.030 |
Why?
|
| Epinephrine | 3 | 1988 | 255 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1998 | 2307 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2001 | 1616 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1995 | 311 | 0.030 |
Why?
|
| Oncogenes | 1 | 1997 | 673 | 0.030 |
Why?
|
| Postoperative Care | 2 | 1996 | 739 | 0.030 |
Why?
|
| Weaning | 1 | 2013 | 45 | 0.030 |
Why?
|
| Karyotyping | 1 | 1995 | 1022 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2015 | 205 | 0.030 |
Why?
|
| Peritonitis | 1 | 2013 | 89 | 0.030 |
Why?
|
| Diarrhea | 1 | 1976 | 686 | 0.030 |
Why?
|
| Amino Acids | 1 | 1996 | 728 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3569 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 1993 | 134 | 0.030 |
Why?
|
| Bone Development | 1 | 2013 | 83 | 0.030 |
Why?
|
| Disease Progression | 2 | 2016 | 6682 | 0.030 |
Why?
|
| Collagen | 1 | 1996 | 752 | 0.030 |
Why?
|
| Professional Practice | 1 | 2012 | 82 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1995 | 875 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2000 | 4892 | 0.030 |
Why?
|
| Tibia | 1 | 2013 | 131 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 1988 | 1271 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 91 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1995 | 1213 | 0.030 |
Why?
|
| Genes | 1 | 1993 | 491 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 3890 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 156 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 884 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2005 | 13658 | 0.030 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1991 | 41 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2015 | 690 | 0.030 |
Why?
|
| Exercise | 1 | 2019 | 1183 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 1399 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1996 | 852 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 233 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 2013 | 241 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2013 | 330 | 0.020 |
Why?
|
| Parathyroidectomy | 2 | 2005 | 203 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 1995 | 1070 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 676 | 0.020 |
Why?
|
| Survival Rate | 3 | 2017 | 12221 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2002 | 305 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2013 | 333 | 0.020 |
Why?
|
| Colforsin | 1 | 1990 | 59 | 0.020 |
Why?
|
| Cattle | 2 | 1995 | 783 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 2927 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1209 | 0.020 |
Why?
|
| France | 1 | 2010 | 108 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2003 | 5542 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1990 | 226 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1992 | 575 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.020 |
Why?
|
| Adrenal Cortex | 2 | 2001 | 35 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2010 | 222 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 2009 | 30 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2014 | 1681 | 0.020 |
Why?
|
| Species Specificity | 1 | 1990 | 777 | 0.020 |
Why?
|
| Optic Chiasm | 1 | 2009 | 40 | 0.020 |
Why?
|
| Pseudohypoparathyroidism | 1 | 1988 | 8 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1996 | 1996 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 558 | 0.020 |
Why?
|
| Consensus Sequence | 2 | 1999 | 117 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 1988 | 190 | 0.020 |
Why?
|
| Parathyroid Diseases | 1 | 1988 | 17 | 0.020 |
Why?
|
| Dihydroxycholecalciferols | 1 | 1987 | 7 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1988 | 334 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1988 | 207 | 0.020 |
Why?
|
| Hypoparathyroidism | 2 | 2003 | 49 | 0.020 |
Why?
|
| Americas | 1 | 2007 | 52 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 1975 | 1058 | 0.020 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 2 | 1999 | 36 | 0.020 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 1998 | 88 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2000 | 682 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 2218 | 0.020 |
Why?
|
| Hot Temperature | 2 | 2001 | 281 | 0.020 |
Why?
|
| Catecholamines | 1 | 1987 | 101 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 829 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2009 | 414 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1983 | 410 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1994 | 2483 | 0.020 |
Why?
|
| Iodide Peroxidase | 1 | 2006 | 26 | 0.020 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2006 | 22 | 0.020 |
Why?
|
| Succinate Dehydrogenase | 1 | 2006 | 43 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 2669 | 0.020 |
Why?
|
| Culture Media | 1 | 1987 | 319 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1986 | 629 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 1313 | 0.020 |
Why?
|
| Adenoviridae | 1 | 1991 | 1459 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Milk | 1 | 2006 | 120 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2006 | 155 | 0.020 |
Why?
|
| Duodenum | 1 | 2006 | 149 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 6009 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 231 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2006 | 274 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2005 | 208 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2006 | 338 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2005 | 213 | 0.020 |
Why?
|
| Potassium | 1 | 1986 | 329 | 0.020 |
Why?
|
| Alleles | 2 | 2001 | 2437 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2003 | 4298 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 202 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 4988 | 0.020 |
Why?
|
| Addison Disease | 1 | 2004 | 8 | 0.020 |
Why?
|
| Litter Size | 1 | 2004 | 26 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 1996 | 869 | 0.020 |
Why?
|
| Growth Plate | 1 | 2004 | 46 | 0.020 |
Why?
|
| Sella Turcica | 1 | 2003 | 24 | 0.010 |
Why?
|
| Placentation | 1 | 2004 | 60 | 0.010 |
Why?
|
| Gamma Cameras | 1 | 2003 | 40 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2004 | 90 | 0.010 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2006 | 275 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1994 | 1797 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1983 | 61 | 0.010 |
Why?
|
| Pregnancy, Animal | 1 | 2004 | 92 | 0.010 |
Why?
|
| Chromatography | 1 | 1983 | 49 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 205 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1983 | 60 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3472 | 0.010 |
Why?
|
| Proline | 1 | 2004 | 130 | 0.010 |
Why?
|
| Biogenic Amines | 1 | 1983 | 15 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 246 | 0.010 |
Why?
|
| Amniotic Fluid | 1 | 2004 | 123 | 0.010 |
Why?
|
| Inheritance Patterns | 1 | 2003 | 139 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1987 | 874 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 525 | 0.010 |
Why?
|
| Skin | 1 | 1989 | 1259 | 0.010 |
Why?
|
| Binding Sites | 2 | 1999 | 2171 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2002 | 77 | 0.010 |
Why?
|
| Nickel | 1 | 2002 | 44 | 0.010 |
Why?
|
| Testosterone | 1 | 2007 | 619 | 0.010 |
Why?
|
| Titanium | 1 | 2002 | 61 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 4320 | 0.010 |
Why?
|
| Neurofibromatosis 1 | 1 | 2004 | 144 | 0.010 |
Why?
|
| Estradiol | 1 | 2006 | 748 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1983 | 266 | 0.010 |
Why?
|
| Neoplasms, Experimental | 3 | 1980 | 750 | 0.010 |
Why?
|
| Thyroxine | 1 | 2002 | 116 | 0.010 |
Why?
|
| Laboratories | 1 | 2003 | 145 | 0.010 |
Why?
|
| Certification | 1 | 2003 | 123 | 0.010 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1983 | 113 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2006 | 533 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 660 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2004 | 7551 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2003 | 201 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 3151 | 0.010 |
Why?
|
| Pregnancy | 2 | 2006 | 7573 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 957 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1983 | 429 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2004 | 262 | 0.010 |
Why?
|
| Chile | 1 | 2001 | 61 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2002 | 220 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2001 | 81 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 1162 | 0.010 |
Why?
|
| Bromocriptine | 1 | 1980 | 8 | 0.010 |
Why?
|
| Sequence Homology | 1 | 2001 | 71 | 0.010 |
Why?
|
| Joints | 1 | 2001 | 47 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2004 | 482 | 0.010 |
Why?
|
| Arginine | 1 | 2004 | 500 | 0.010 |
Why?
|
| Models, Biological | 1 | 1990 | 3254 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1487 | 0.010 |
Why?
|
| Neutropenia | 1 | 2005 | 968 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1980 | 68 | 0.010 |
Why?
|
| Levodopa | 1 | 1980 | 92 | 0.010 |
Why?
|
| Glucagon | 1 | 1980 | 196 | 0.010 |
Why?
|
| Reaction Time | 1 | 2001 | 234 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 575 | 0.010 |
Why?
|
| Substance P | 1 | 2000 | 71 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 516 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2003 | 590 | 0.010 |
Why?
|
| Splicing Factor U2AF | 1 | 1999 | 48 | 0.010 |
Why?
|
| Metallothionein | 1 | 1998 | 34 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 6100 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 1239 | 0.010 |
Why?
|
| Vertebrates | 1 | 1998 | 68 | 0.010 |
Why?
|
| CHO Cells | 1 | 1999 | 311 | 0.010 |
Why?
|
| Ethanol | 1 | 1980 | 264 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 899 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10001 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 1498 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2001 | 709 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1976 | 28 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1980 | 1519 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2001 | 953 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 4143 | 0.010 |
Why?
|
| Probability | 2 | 1989 | 866 | 0.010 |
Why?
|
| Biomarkers | 1 | 2008 | 5047 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 844 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2002 | 1529 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 3981 | 0.010 |
Why?
|
| Mouth Diseases | 1 | 1996 | 34 | 0.010 |
Why?
|
| Vaginal Diseases | 1 | 1996 | 26 | 0.010 |
Why?
|
| Nucleotides | 1 | 1996 | 164 | 0.010 |
Why?
|
| Mitotane | 1 | 1995 | 39 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1995 | 73 | 0.010 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 1996 | 60 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2006 | 2819 | 0.010 |
Why?
|
| Duodenal Neoplasms | 1 | 1976 | 138 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 397 | 0.010 |
Why?
|
| Sheep | 1 | 1995 | 258 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 2232 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1977 | 419 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1994 | 34 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1994 | 82 | 0.010 |
Why?
|
| Templates, Genetic | 1 | 1994 | 86 | 0.010 |
Why?
|
| China | 1 | 1996 | 606 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 997 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1996 | 665 | 0.010 |
Why?
|
| Mortality | 1 | 1996 | 343 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1995 | 369 | 0.010 |
Why?
|
| Anthracyclines | 1 | 1996 | 331 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1980 | 2843 | 0.010 |
Why?
|
| Haplotypes | 1 | 1996 | 856 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1995 | 402 | 0.010 |
Why?
|
| Mesoderm | 1 | 1995 | 404 | 0.010 |
Why?
|
| Pancreas | 1 | 1996 | 718 | 0.010 |
Why?
|
| Leukocytes | 1 | 1994 | 422 | 0.010 |
Why?
|
| Lod Score | 1 | 1992 | 157 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2341 | 0.010 |
Why?
|
| Cytoplasmic Granules | 2 | 1983 | 89 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1977 | 1506 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 1993 | 690 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 1993 | 652 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1988 | 425 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 1988 | 137 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 1994 | 895 | 0.000 |
Why?
|
| Kidney | 2 | 1988 | 2146 | 0.000 |
Why?
|
| Glomerular Filtration Rate | 1 | 1988 | 602 | 0.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1994 | 1664 | 0.000 |
Why?
|
| Propranolol | 1 | 1983 | 156 | 0.000 |
Why?
|
| Clone Cells | 1 | 1983 | 555 | 0.000 |
Why?
|
| Microbial Collagenase | 1 | 1980 | 17 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 600 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 4557 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1980 | 548 | 0.000 |
Why?
|
| Basement Membrane | 1 | 1979 | 138 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1978 | 275 | 0.000 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 1977 | 34 | 0.000 |
Why?
|
| Graves Disease | 1 | 1977 | 50 | 0.000 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1976 | 7 | 0.000 |
Why?
|
| Gastrins | 1 | 1976 | 55 | 0.000 |
Why?
|
| Cell Division | 1 | 1980 | 2489 | 0.000 |
Why?
|
| Organ Size | 1 | 1976 | 690 | 0.000 |
Why?
|
| Macrophages | 1 | 1977 | 1304 | 0.000 |
Why?
|
| Aging | 1 | 1979 | 1582 | 0.000 |
Why?
|